Arrowhead Pharmaceuticals, Inc. (ARWR) — Fair Value Analysis

Base-case fair value (P50): $69.21 · Current price: $77.53 · Verdict: Fairly Valued

The Verdict on ARWR

ARROWHEAD PHARMACEUTICALS INC (ARWR) is currently deemed Fairly Valued by our Monte Carlo simulations. The stock’s present trading price of $77.53 stands above our median fair value (P50) of $69.21, representing a -10.7% difference. While this gap indicates ARWR is trading modestly above its central fair value estimate, the comprehensive probabilistic analysis suggests the stock is not overtly overvalued. Investors should note this Fairly Valued assessment as a guide to ARWR's current market position relative to its intrinsic value, accounting for various future scenarios.

How ARWR stacks up against peers

ARWR's operational and financial health is categorized as an average quality tier when compared against its sector peers. This mid-tier standing implies that while ARROWHEAD PHARMACEUTICALS INC demonstrates fundamental stability and acceptable performance, it does not exhibit the exceptional characteristics that might justify a significant premium in valuation. This average quality tier plays a crucial role in our Monte Carlo assessment, helping to contextualize the median fair value of $69.21. The current price of $77.53 trading -10.7% above this median, yet resulting in a Fairly Valued verdict, reflects the market's current assessment against a company with an average fundamental strength.

What this means for investors

For investors, ARWR's current price of $77.53, positioned -10.7% above the median fair value of $69.21, combined with an average quality tier, points to a balanced, rather than aggressively overstretched, valuation. Despite the current trading price exceeding the P50, the full Monte Carlo distribution, accounting for thousands of forward scenarios, concludes ARROWHEAD PHARMACEUTICALS INC is Fairly Valued. This suggests that while a downside scenario is implied by the median, the market is not excessively penalizing or rewarding ARWR at its current level. The FairCurve analysis indicates the stock is trading near a justifiable level. To fully understand ARWR's potential upside and downside scenarios, including the complete bear and bull distribution, sign up for FairCurve to track its fair value as new fundamentals are released.